Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Impact of renal insufficiency on mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

  • Jonas Emil Sabroe1,
  • Per Thayssen1,
  • Lisbeth Antonsen1,
  • Mikkel Hougaard1,
  • Knud Nørregaard Hansen1 and
  • Lisette Okkels Jensen1Email author
BMC Cardiovascular Disorders201414:15

DOI: 10.1186/1471-2261-14-15

Received: 7 July 2013

Accepted: 28 January 2014

Published: 7 February 2014

Abstract

Background

Chronic kidney disease is associated with increased risk of mortality. We examined the impact of moderate and severe renal insufficiency (RI) on short- and long-term mortality among unselected patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).

Methods

From January 1, 2002 to December 31, 2010 all patients with STEMI treated with primary PCI were identified. The hazard ratio (HR) for death was estimated using a Cox regression model, controlling for potential confounders. RI was defined as creatinine clearance (CrCl) < 60 mL/min (moderate RI: CrCl ≤30 < 60 mL/min and severe RI: CrCl < 30 mL/min).

Results

The study cohort consisted of 4,116 patients of whom 898 (21.8%) had RI and 3,218 (78.2%) had a CrCl ≥ 60 mL/min. Compared to patients without RI, patients with RI were older, more often female and more likely to have diabetes mellitus, hypertension and to present with a higher Killip class.

Among patients with a preserved kidney function and patients with RI, 30-day all-cause mortality was 3.5% vs. 20.9% (log-rank p < 0.001); 1-year all-cause mortality was 5.7% vs. 29.4% (log-rank p < 0.001); 5-year all-cause mortality was 13.4% vs. 47.4% (log-rank p < 0.001). Moderate and severe RI were associated with higher 1-year mortality compared to patients with a preserved renal function (CrCl ≤30 < 60 mL/min: adjusted HR 2.71 [95% CI 2.09-3.51], p < 0.001), and (CrCl < 30 mL/min: adjusted HR 7.09 [4.82-10.44], p < 0.001).

Conclusion

In unselected STEMI patients treated with primary PCI, moderate and severe RI were associated with increased risk of mortality.

Keywords

ST-segment elevation myocardial infarction Renal insufficiency Mortality

Background

Cardiovascular disease (CVD) is a leading cause of death in the western countries [1]. Studies have shown that impaired renal function is to be considered a risk factor in relation to CVD and patients suffering from renal disease have a higher risk of CVD [24]. Also, chronic kidney disease (CKD) is found to be strongly associated with an increased risk of myocardial infarction (MI) and CVD mortality [5, 6]. Furthermore, CKD is found to affect patients on a global scale and with an increasing incidence and prevalence [7]. After ST-segment elevation MI (STEMI) and non-STEMI the mortality has been reported to be significantly higher among patients with renal disease compared to patients with preserved renal function [810]. Today primary PCI is the recommended reperfusion strategy when treating patients with STEMI, which also applies to STEMI patients with renal dysfunction [11]. Limited data are available on the outcome after primary PCI in STEMI patients with RI, because they have been underrepresented in randomized trials, as renal failure is a commonly used exclusion criterion [12].

In our study, data from the Western Denmark Heart Registry (WDHR) were used in order to assess the impact of moderate and severe renal insufficiency (RI) on short- and long-term mortality among unselected STEMI patients treated with primary PCI. Primary PCI has been the recommended treatment for STEMI after publication of the results of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2) in 2003 [13].

Methods

Setting and design

The study was conducted using WDHR for patients treated at Odense University Hospital. A detailed description of the databases has been reported previously [14]. The study was a registry study and ethical approval was not required.

Patients and procedures

To be eligible for primary PCI, patients must meet the following criteria: 1) symptoms present less than 12 hours from onset of pain to time of catheterization, and 2) ST-segment elevation (at least 0.1 mV in two or more standard leads or at least 0.2 mV in two or more contiguous pre-cordial leads) or a new left bundle-branch block (LBBB). Patient with cardiogenic shock were not excluded. We used the WDHR to identify all primary PCIs performed from January 1, 2002 through December 31, 2010. Drug eluting stent (DES), bare metal stent (BMS), glycoprotein IIb/IIIa receptor blocker, and intra-aortic balloon pump was administered at the operator’s discretion. All patients received antiplatelet regimen including a bolus of 10,000 IU heparin, lifelong acetylsalicylic acid (75–150 mg once daily), and clopidogrel with a loading dose of 300 mg followed by maintenance with 75 mg daily. The recommended duration of clopidogrel treatment was 3 to 12 months until November 2002 and 12 months thereafter.

Blood samples were taken from the arterial sheath before the first contrast injection and serum creatinine - concentration was assessed in the hospital laboratory. Estimation of renal function is commonly based on estimated creatinine clearance (CrCl). Different methods are available. Studies have shown that The Modification of Diet in Renal Disease (MDRD) formula gives a reliable estimated CrCl [1517], representing estimated glomerular filtration ratio (eGFR). Therefore the MDRD formula was used in this study: eGFR = estimated CrCl = 186 × standardized S-Cr-1.154 × age-0.203 × 0.742 [if female] [18]. The unit of this equation is expressed as mL/min per 1.73 m2 body surface area. An eGFR less than 60 mL/min per 1.73 m2 was considered equivalent to RI. Based on eGFR the study population was divided into three groups, a group with eGFR ≥ 60 mL/min per 1.73 m2, a group with moderate RI: CrCl ≤30 < 60 mL/min per 1.73 m2, and a group with severe RI: CreaCl < 30 mL/min per 1.73 m2. This classification of patients into different stages of CKD is identical with those universally endorsed and based on the National Kidney Foundation data [7] where patients with an eGFR ≥ 60 mL/min per 1.73 m2 is STAGE I/II, patients with 30 ≤ eGFR < 60 mL/min per 1.73 m2 are in STAGE III, and patients with eGFR < 30 mL/min per 1.73 m2 are in STAGE IV/V.

Endpoints

Primary end-point of the study was all cause-mortality rate. Data on mortality were obtained from the Danish Civil Registration System [19, 20], which has kept electronic records on the gender, date of birth, changes in address, date of emigration, and changes in vital status of the entire Danish population since 1968.

Statistics

Continuous variables were presented as medians with inter quartile range (IQR 25th, 75th) or mean ± 1 standard deviations (SD). Medians were compared using the Mann–Whitney U test, and means were compared using the unpaired t test. Categorical variables were presented as numbers and percentages. Distributions of categorical variables were compared using the Chi-square test.

We counted end-point events that occurred during the follow-up period and compared rates for the two groups (CrCl ≥60 mL/min per 1.73 m2 vs. CrCl <60 mL/min per 1.73 m2). Follow-up began on the date of primary PCI procedure and continued until date of death, December 31, 2010 or after 5 years follow-up (to ensure at least 10% of the study population at risk), whichever came first. Kaplan-Meier curves for all-cause mortality according to kidney function (CrCl ≥ 60 mL/min per 1.73 m2, CrCl ≤30 < 60 mL/min per 1.73 m2 and CrCl <30 mL/min per 1.73 m2) were obtained.

Cox proportional hazards regression analysis was used to estimate the hazard ratio (HR) mortality. Crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were computed. Potential confounders associated with time to death in the univariable Cox regression analysis were included in the multivariable Cox regression model. Thus, in the final model, we adjusted for RI, age diabetes mellitus, hypertension, previous myocardial infarction, treatment with glycoprotein IIb/IIIa receptor blocker, Killip class and duration of procedure. All data analyses were carried out using SPSS software version 20. A two-sided P value <0.05 was considered significant.

Results

A total of 4,676 consecutive patients were treated with primary PCI for STEMI or new onset LBBB MI at Odense University Hospital between January 1, 2002 and December 31, 2010. Mortality data was not available for 83 patients, who were foreign citizens. Patients undergoing a later acute MI after the first index procedure (n = 223) were excluded. In 254 patients the creatinine values were not available. Thus, the final study population consisted of 4,116 patients; of these were 898 patients diagnosed with RI, defined as CrCl < 60 mL/min per 1.73 m2, and 3,218 patients had a preserved kidney function (Figure 1).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2261-14-15/MediaObjects/12872_2013_Article_671_Fig1_HTML.jpg
Figure 1

Flow diagram of participant selection.

Baseline characteristics of patients with RI and patients with a preserved kidney function are listed in Table 1. Patients with RI were older and more likely to be female, to have diabetes, hypertension, previous MI, hypercholesterolemia and less likely to be smokers. Among patients with RI, patients with severe RI (CrCl < 30 mL/min per 1.73 m2) more often had diabetes. Characteristics of angiographic findings, lesions and treatment procedures also differed between patients with normal and reduced CrCl, respectively. Patients with RI were more likely to have multi-vessel disease, a higher Killip class, left main culprit lesion, more complex lesions and longer duration of procedure. Patients with RI were less often treated with DES (Table 2).
Table 1

Baseline clinical characteristics according to kidney function

 

CrCl ≥ 60

Valid cases

CrCl < 60

Valid cases

Pvalue (CrCl ≥ 60 vs. CrCl < 60)

CrCl ≤30 < 60

CrCl < 30

Pvalue (CrCl < 30 vs. CrCl ≤30 < 60)

Number of patients - no.

3,218

3,218

898

898

 

810

88

 

Male gender - no. (%)

2,486 (77.3)

3,218

524 (58.4)

898

<0.001

471 (58.1)

53 (60.2)

0.707

Age – (year)

61.5 ± 12.1

3,218

73.5 ± 11.0

898

<0.001

73.5 ± 10.8

72.8 ± 12.8

0.532

Family history - no. (%)

1,235 (39.8)

3103

194 (23.5)

824

<0.001

178 (23.8)

16 (20.8)

0.548

Smoking - no. (%)

1,712 (57.2)

2991

290 (39.1)

741

<0.001

257 (38.1)

33 (49.3)

0.075

Body Mass Index – (kg/m2)

26.8 (4.4)

2,132

26.6 (4.6)

507

0.256

26.7 (4.6)

24.9 (4.2)

0.009

Diabetes - no. (%)

272 (8.5)

3218

120 (13.4)

898

<0.001

101 (12.5)

19 (21.6)

0.017

Hypertension - no. (%)

930 (29.2)

3,180

404 (46.6)

867

<0.001

358 (45.8)

46 (54.1)

0.143

Previous coronary artery bypass grafting - no. (%)

64 (2.0)

3,214

23 (2.6)

893

0.283

21 (2.6)

2 (2.3)

1.000

Previous percutaneous coronary intervention - no. (%)

203 (6.4)

3,164

58 (6.7)

868

0.778

48 (6.1)

10 (11.8)

0.048

Previous myocardial infarction - no. (%)

330 (10.4)

3,168

127 (14.5)

875

0.001

108 (13.7)

19 (13.7)

0.31

Lipid lowering therapy - no. (%)

617 (19.4)

3,173

201 (23.2)

866

0.015

173 (22.2)

28 (32.9)

0.025

Glycoprotein IIb/IIIa receptor blocker – no. (%)

1,445 (48.2)

2,998

285 (34.4)

828

<0.001

263 (35.8)

22 (26.5)

0.110

Systolic blood pressure - (mmHg)

122.9 ±24.9

2,467

118.1 ±30.5

662

<0.001

118.7 ±30.3

112.4 ±32.0

0.118

Diastolic blood pressure - (mmHg)

71.8 ±13.9

2,449

66.0 ± 15.1

654

<0.001

66.4 ± 15.1

62.3 ± 15.9

0.043

Table 2

Angiographic and procedural characteristics according to kidney function

 

CrCl ≥ 60

Valid cases

CrCl < 60

Valid cases

Pvalue (CreaCl ≥ 60 vs. CreaCl < 60)

CrCl ≤30 < 60

CrCl < 30

Pvalue (CrCl < 30 vs. CrCl ≤30 < 60)

Number of patients - no.

3,218

3,218

898

898

 

810

88

 

Multivessel disease no. (%)

1,304 (41.6)

3,135

520 (59.4)

876

<0.001

464 (58.7)

56 (65.9)

0.198

Infarct related artery –no. (%)

 

3,144

 

867

<0.001

  

0.230

  Left anterior descending artery - no. (%)

1,383 (44.0)

 

340 (39.2)

  

314 (40.2)

26 (30.6)

 

  Left circumflex artery - no. (%)

451 (14.3)

 

109 (12.6)

  

100 (12.6)

9 (10.6)

 

  Right coronary artery - no. (%)

1,252 (39.8)

 

374 (43.1)

  

329 (42.1)

45 (52.9)

 

  Left main - no. (%)

58 (1.8)

 

44 (5.1)

  

39 (5.0)

5 (5.9)

 

Anterior STEMI or LBBB – no. (%)

1,401 (45.2)

3,100

372 (43.1)

864

<0.001

343 (43.8)

29 (35.8)

0.100

Killip class – no. (%)

 

3,152

 

878

<0.001

  

0.001

  I

2,925 (92.8)

 

676 (77.0)

  

624 (78.5)

52 (62.7)

 

  II

135 (4.3)

 

62 (7.1)

  

55 (6.9)

7 (8.4)

 

  III

51 (1.6)

 

51 (5.8)

  

46 (5.8)

5 (6.0)

 

  IV

41 (1.3)

 

89 (10.1)

  

70 (8.8)

19 (22.9)

 

Preintervention TIMI flow – no. (%)

 

3,143

 

863

0.248

  

0.891

  Grade 0

2,198 (54.2)

 

2,794 (58.7)

  

438 (56.2)

49 (59.9)

 

  Grade 1

265 (6.5)

 

282 (5.9)

  

51 (6.5)

4 (4.8)

 

  Grade 2

597 (14.7)

 

623 (13.1)

  

117 (15.0)

11 (13.3)

 

  Grade 3

978 (24.1)

 

1,052 (22.1)

  

174 (22.3)

19 (22.9)

 

Final TIMI flow - no. (%)

 

3,143

 

863

<0.001

  

0.097

  Grade 0

73 (2.3)

 

50 (5.8)

  

41 (5.3)

9 (10.8)

 

  Grade 1

28 (0.9)

 

20 (2.3)

  

20 (2.6)

0 (0.0)

 

  Grade 2

166 (5.3)

 

78 (9.0)

  

70 (9.0)

8 (9.6)

 

  Grade 3

2,876 (91.5)

 

715 (82.9)

  

649 (83.2)

66 (79.5)

 

Lesion length – mm median (IQR)

15.00 (10.0-20.0)

3,110

15.0 (10.0-20.0)

855

0.676

15.00 (10.0-20.0)

15.00 (10.0-20.0)

0.318

Reference segment – mm median (IQR)

3.3 (3.0-3.6)

3,120

3.2 (3.0-3.5)

851

0.007

3.2 (3.0-3.5)

3.2 (2.8-3.5)

0.320

Minimum lumen diameter – mm median (IQR)

0.0 (0.0-0.2)

3,134

0.0 (0.0-0.2)

859

0.749

0.0 (0.0-0.2)

0.0 (0.0-0.2)

0.625

Sapheneous vein graft – no. (%)

10 (0.3)

3,145

4 (0.5)

867

0.526

2 (0.3)

2 (2.4)

0.007

Lesion type B2/C

1,012 (32.9)

3,082

338 (40.3)

838

<0.001

302 (39.7)

36 (46.2)

0.041

Stent length – mm median (IQR)

18.0 (14.0-23-0)

2,963

18.0 (14.0-24.0)

754

0.913

18.0 (14.0-24.0)

18.0 (13.0-24.0)

0.830

Stent number - no. (%)

 

3,218

 

898

<0.001

  

0.007

  0

255 (7.9)

 

144 (16.0)

  

120 (14.8)

24 (27.3)

 

  1

2,578 (80.1)

 

643 (71.6)

  

591 (73.0)

52 (59.1)

 

  2+

385 (12.0)

 

111 (12.4)

  

99 (12.2)

12 (13.6)

 

Drug-eluting stent – no. (%)

1,962 (62.4)

3,146

366 (41.4)

885

<0.001

338 (42.3)

28 (32.6)

0.007

Max balloon pressure – atm median (IQR)

16.0 (14.0-18.0)

3,075

15.5 (14.0-17.3)

814

0.086

15.5 (14.0-17.0)

15.5 (14.0-18.0)

0.899

Max balloon diameter – mm median (IQR)

3.6 (3.2-3.8)

3,073

3.4 (3.2-3.8)

814

0.012

3.4 (3.2-3.8)

3.3 (3.0-3.7)

0.126

Duration of procedure - minutes median (IQR)

16.0 (10.0-26.0)

3,205

17.0 (11.0-28.0)

895

0.008

17.0 (11.0-28.0)

20.0 (12.0-30.8)

0.238

Flouro time - minutes median (IQR)

6.4 (4.0-11.2)

3,174

7.7 (4.5-13.0)

878

< 0.001

7.5 (4.4-13.0)

9.0 (6.0-13.3)

0.077

Contrast – ml median (IQR)

120.0 (75.0-180.0)

877

100.0 (75.0-175.0)

3,159

0.007

120.0 (75.0-185.0)

110.0 (80.0-174.0)

0.572

STEMI: ST-segment elevation myocardial infarct.

LBBB: new onset left bundle branch block.

IQR: Interquartile range.

The median follow-up interval was 3.3 years (25th – 75th percentile: 1.4-5.0 years), with a 1-year mortality of 10.7% (n = 441) and 5-year mortality of 17.2% (n = 707). Among patients with a preserved kidney function and patients with RI, 30-day all-cause mortality was 3.5% (n = 112) and 20.9% (n = 188), respectively (log-rank p < 0.001); 1-year all-cause mortality was 5.7% (n = 179) and 29.4% (n = 262), respectively (log-rank p < 0.001); 5-year all-cause mortality was 13.4% (n = 328) and 47.4% (n = 379), respectively (log-rank p < 0.001). Figure 2 shows the 5-year all-cause survival of the study population when stratified into two groups with CrCl < 60 mL/min per 1.73 m2 and CrCl ≥ 60 mL/min per 1.73 m2 respectively.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2261-14-15/MediaObjects/12872_2013_Article_671_Fig2_HTML.jpg
Figure 2

Kaplan-Meier curves for all-cause mortality in patients with CrCl < 60 mL/min per 1.73 m 2 and CrCl ≥ 60 mL/min per 1.73 m 2 .

Among patients with RI (group 1: CrCl <30 mL/min per 1.73 m2 and group 2: CrCl ≤30 < 60 mL/min per 1.73 m2) the all-cause mortality rates were: at 30-day, 40.9% (n = 36) group 1 vs. 18.8% (n = 152) group 2 (log rank p < 0.001); at 1-year, 57.5% (n = 50) group 1 vs. 26.4% (n = 212) group 2 (log rank p < 0.001) and at 5-year, 71.3% (n = 58) group 1 and 44.8% (n = 321) group 2 (log rank p < 0.001). Figure 3 shows the 5-year all-cause survival of STEMI patients when stratified into three groups based on CrCl.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2261-14-15/MediaObjects/12872_2013_Article_671_Fig3_HTML.jpg
Figure 3

Kaplan-Meier curves for all-cause mortality in patients with CrCl <30 mL/min per 1.73 m 2 vs. CrCl ≤30 < 60 mL/min per 1.73 m 2 and CrCl ≥60 mL/min per 1.73 m 2 .

Table 3 shows the crude HR associated with 1-year mortality. CrCl < 60 mL/min, diabetes, hypertension, previous myocardial infarction and increasing Killip class were associated with an increased mortality. Male gender and treatment with glycoprotein IIb/IIIa receptor blocker were associated with a lower mortality.
Table 3

crude and adjusted hazard ratio of covariates associated with 1-year mortality in Cox regression analysis

 

Valid cases

Crude hazard ratio (95% CI)

Pvalue

Adjusted hazard ratio (95% CI)

Pvalue

Male gender

4,116

0.68 (0.56-0.83)

<0.001

1.11 (0.88-1.41)

0.354

Creatinine clearance

4,116

 

<0.001

 

<0.001

   Creatinine clearance ≥ 60 mL/min

 

Reference

 

Reference

 

   Creatinine clearance ≤30 < 60 mL/min

 

5.31 (4.35-6.49)

 

2.71 (2.09-3.51)

 

   Creatinie clearance < 30 mL/min

 

15.37 (11.27-21.04)

 

7.09 (4.82-10.44)

 

Age – years

4,116

1.07 (1.06-1.08)

<0.001

1.04 (1.03-1.06)

<0.001

Diabetes mellitus

4,116

2.47 (1.95-3.13)

<0.001

1.77 (1.33-2.35)

<0.001

Hypertension

4,047

1.26 (1.03-1.53)

0.025

1.40 (1.11-1.76)

0.004

Previous myocardial infarction

4,043

1.99 (1.57-2.53)

<0.001

1.53 (1.14-2.07)

0.006

Glycoprotein IIb/IIIa receptor blocker

3,826

0.49 (0.40-0.61)

<0.001

0.68 (0.53-0.86)

<0.001

Multivessel disease

4,011

2.32 (1.91-2.83)

<0.001

1.15 (0.90-1.46)

0.265

Infarct related artery

4,011

 

<0.001

 

0.023

   Right coronary artery

 

Reference

 

Reference

 

   Left anterior descending artery

 

1.19 (0.96-1.48)

 

1.31 (1.03-1.68)

 

   Left circumflex artery

 

1.02 (0.74-1.40)

 

1.24 (0.88-1.74)

 

   Left main

 

4.02 (2.73-5.92)

 

1.92 (1.20-3.08)

 

Killip class

4,030

 

<0.001

 

<0.001

   I

 

Reference

 

Reference

 

   II

 

2.32 (1.64-3.30)

 

1.20 (1.20-2.69)

 

   III

 

4.54 (3.17-6.51)

 

1.68 (1.68-3.79)

 

   IV

 

9.55 (7.32-12.46)

 

1.86 (2.86-5.75)

 

Duration of procedure - minutes

4,100

1.01 (1.01-1.02)

<0.001

1.01 (1.00-1.01)

0.007

After adjustment for potential confounders (Table 3) we found CrCl, diabetes, age, hypertension and Killip class to be associated with increased 1-year mortality. After adjustment for covariates associated with mortality, RI was associated with increased mortality at 30-day (adjusted HR 2.38, 95% CI 1.34-4.21), 1-year (adjusted HR 2.29, 95% CI 1.50-3.50) and 5-year mortality (adjusted HR 2.02, 95% CI 1.50-2.72) compared to patients with preserved kidney function.

Discussion

Based on an unselected cohort of STEMI patients this study aimed to explore the impact of renal disease on all-cause mortality among 4,116 STEMI patients treated with primary PCI. In this real-world setting we found, that RI was associated with increased short- and long-term mortality. The strength of the present study is that the patients are unselected, all-comer and consecutive. Today guidelines suggest, that patients with STEMI and renal dysfunction is treated in the same way as other STEMI patients with the exception of administration of contrast dye and some medications [11]. However, as primary PCI in STEMI patients is an emergent therapy; neither the kidney function nor the creatinine clearance level will be known in these patients at the time of the primary PCI. In our registry, most of the patients were diagnosed prehospital in the ambulance and referred directly to the catheterization laboratory, where the first blood sample was collected from the arterial sheath before contrast injection. In a recent study Fox et al. [12] showed from the Acute Coronary Treatment and Intervention Outcome Network (ACTION) registry, that one third of patients with STEMI had an eGFR < 60 mL/min per 1.73 m2. This is a higher number than the 22% of patients with RI we found in our study, which may be related to the patient population, as patients in the ACTION registry had a different comorbidity risk, as the rate of diabetes mellitus and hypertension were 2 to 3 times higher in the ACTION registry compared to our registry data. In contrast to our study, Fox et al. described that information about kidney function were available to the treating physicians when therapeutic decisions were made, and only 90% of patients with STEMI received reperfusion therapy (80% as primary PCI and 10% were treated with fibrinolysis). In our study patients with RI were more likely to receive primary PCI without stent implantation and less likely to receive treatment with glycoprotein IIb/IIIa receptor blocker compared to patients without RI. Among 2,597 STEMI and non-STEMI patients Medi et al. [21] found, that patients with RI and comorbidity were less likely to undergo coronary angiography, despite having the same frequency of primary PCI treatment as non-RI patients after angiography.

In our real-world setting registry we found, that RI was associated with increased short- and long-term mortality. This is in accordance with previous studies where RI also has been found to be associated with a higher 30-days mortality and long term mortality [2225]. Seyfarth et al. [26] found an increase in adjusted hazard ratio after one year follow-up of 1.20 per 10-mL/min decrease in eGFR. In a study of Morel et al. [27] STEMI and non-STEMI patients were found to have a higher 9-month all-cause mortality when diagnosed with renal disease. Sadeghi et al. [28] studied 1,933 patients from the “Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC)” trial, where baseline creatinine levels were obtained before angiography, including 350 patients with RI defined as CrCl < 60 mL/min per 1.73 m2. In our registry cohort, both short-term and 1-year mortality rate was more than twice as high as in the study from Sadeghi et al. [28]. This difference is probably caused by (1) an increased mortality risk in non-randomized and all-comer patients compared to results from a randomized controlled study and (2) that patients with cardiogenic shock were not excluded in our study. Bertomeu-Gonzales et al. [29] studied the relationship between Killip class and impact of renal disease on mortality and found, that renal disease was stronger associated with mortality in STEMI patients with Killip I compared to patients with a higher Killip class. In our study, patients with RI were more likely to be older and female and they were more likely to have diabetes, hyperlipidemia, and hypertension. The finding of women representing a large proportion of STEMI patients with RI is consistent with findings from other studies [10, 28, 30, 31]. RI was found to be an independent predictor of 1-year mortality whereas we did not find gender to be an independent risk factor for 1-year mortality when adjusted for confounders. Similar findings have been made by Damman et al. [32] where 3-year mortality was found to be associated with a decrease in renal function, whereas gender difference was not proven to be a predictor of mortality after adjustment for confounders.

Limitations

The validity of our findings depends on data quality and the ability to control for potential confounding. Like all observational studies, our study is prone to biases related to unmeasured factors. Bias due to unknown variables cannot be eliminated. Patients with cardiogenic shock were not excluded from the present study. We did not have systematically access to creatinine values taken in the following days after the primary PCI or information about contrast-induced nephropathy. Patients with RI were more often treated with balloon dilatation without stent implantation or bare metal stent. One explanation for this treatment strategy may be related to the more common finding of severely calcified lesions, which are known to limit complete DES expansion. We also lacked data on causes of mortality, however, in a previous STEMI cohort from Western Denmark Heart Registry, we found that especially the early causes of death was caused by a cardiac reason: the 1-year mortality reason was cardiac in 75% of the patients, whereas the 3-year mortality reason is cardiac death in 60% of the patients [33].

Conclusion

In unselected STEMI patients treated with primary PCI, RI was associated with increased short- and long-term mortality compared to patients with a preserved kidney function.

Declarations

Authors’ Affiliations

(1)
Department of Cardiology, Odense University Hospital

References

  1. Mendis S: Cardiovascular risk assessment and management in developing countries. Vasc Health Risk Manag. 2005, 1: 15-18. 10.2147/vhrm.1.1.15.58933.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Ichikawa K, Konta T, Ikeda A, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, Asahi K, Kurahashi I, Ohashi Y, Watanabe T: Significance of past history of renal failure for the detection of high-risk individuals for cardiovascular and end-stage renal disease: analysis of data from a nationwide health checkup. Clin Exp Nephrol. 2011, 15: 841-847. 10.1007/s10157-011-0509-y.View ArticlePubMedGoogle Scholar
  3. Furuhashi T, Moroi M, Joki N, Hase H, Masai H, Kunimasa T, Nakazato R, Fukuda H, Sugi K: The impact of chronic kidney disease as a predictor of major cardiac events in patients with no evidence of coronary artery disease. J Cardiol. 2010, 55: 328-336. 10.1016/j.jjcc.2009.12.009.View ArticlePubMedGoogle Scholar
  4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056/NEJMoa041031.View ArticlePubMedGoogle Scholar
  5. Meisinger C, Doring A, Lowel H: Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006, 27: 1245-1250.View ArticlePubMedGoogle Scholar
  6. Manjunath G, Tighiouart H, Ibrahim H, Macleod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003, 41: 47-55.View ArticlePubMedGoogle Scholar
  7. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, National Kidney F.: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139: 137-147. 10.7326/0003-4819-139-2-200307150-00013.View ArticlePubMedGoogle Scholar
  8. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002, 137: 563-570. 10.7326/0003-4819-137-7-200210010-00007.View ArticlePubMedGoogle Scholar
  9. Menon V, Sarnak MJ, Lessard D, Goldberg RJ: Recent trends in hospital management practices and prognosis after acute myocardial infarction in patients with kidney disease. Am J Cardiol. 2004, 94: 1290-1293. 10.1016/j.amjcard.2004.07.116.View ArticlePubMedGoogle Scholar
  10. Seyfarth M, Kastrati A, Mann JF, Ndrepepa G, Byrne RA, Schulz S, Mehilli J, Schomig A: Prognostic value of kidney function in patients with st-elevation and non-st-elevation acute myocardial infarction treated with percutaneous coronary intervention. Am J Kidney Dis. 2009, 54: 830-839. 10.1053/j.ajkd.2009.04.031.View ArticlePubMedGoogle Scholar
  11. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ’t Hof A, Widimsky P, Zahger D: Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012, 33: 2569-2619.View ArticlePubMedGoogle Scholar
  12. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD: Use of evidence-based therapies in short-term outcomes of st-segment elevation myocardial infarction and non-st-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the national cardiovascular data acute coronary treatment and intervention outcomes network registry. Circulation. 2010, 121: 357-365. 10.1161/CIRCULATIONAHA.109.865352.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen L: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003, 349: 733-742. 10.1056/NEJMoa025142.View ArticlePubMedGoogle Scholar
  14. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L: Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007, 50: 463-470. 10.1016/j.jacc.2007.06.002.View ArticlePubMedGoogle Scholar
  15. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT: Performance of the cockcroft-gault, mdrd, and new ckd-epi formulas in relation to gfr, age, and body size. Clin J Am Soc Nephrol. 2010, 5: 1003-1009. 10.2215/CJN.06870909.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Rigalleau V, Lasseur C, Perlemoine C, Barthe N, Raffaitin C, Chauveau P, Combe C, Gin H: Cockcroft-gault formula is biased by body weight in diabetic patients with renal impairment. Metabolism. 2006, 55: 108-112. 10.1016/j.metabol.2005.07.014.View ArticlePubMedGoogle Scholar
  17. Fesler P, Mimran A: Estimation of glomerular filtration rate: what are the pitfalls?. Curr Hypertens Rep. 2011, 13: 116-121. 10.1007/s11906-010-0176-5.View ArticlePubMedGoogle Scholar
  18. Hallan S, Asberg A, Lindberg M, Johnsen H: Validation of the modification of diet in renal disease formula for estimating gfr with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004, 44: 84-93. 10.1053/j.ajkd.2004.03.027.View ArticlePubMedGoogle Scholar
  19. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB: The danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006, 53: 441-449.PubMedGoogle Scholar
  20. Epidemiology FL: When an entire country is a cohort. Science. 2000, 287: 2398-2399. 10.1126/science.287.5462.2398.View ArticleGoogle Scholar
  21. Medi C, Chew DP, Amerena J, Coverdale S, Soman A, Astley C, Rankin J, Brieger D: An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease. Intern Med J. 2011, 41: 743-750. 10.1111/j.1445-5994.2010.02361.x.View ArticlePubMedGoogle Scholar
  22. Campbell NG, Varagunam M, Sawhney V, Ahuja KR, Salahuddin N, De PR, Rothman MT, Wragg A, Yaqoob MM, Knight CJ: Mild chronic kidney disease is an independent predictor of long-term mortality after emergency angiography and primary percutaneous intervention in patients with st-elevation myocardial infarction. Heart. 2012, 98: 42-47. 10.1136/heartjnl-2011-300024.View ArticlePubMedGoogle Scholar
  23. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E: Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003, 42: 1535-1543. 10.1016/j.jacc.2003.06.001.View ArticlePubMedGoogle Scholar
  24. Wilson WM, Andrianopoulos N, Clark D, Duffy SJ, Brennan A, Harries I, New G, Sebastian M, Loane P, Reid C, Ajani AE: Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stents. Am J Cardiol. 2011, 108: 936-942. 10.1016/j.amjcard.2011.05.024.View ArticlePubMedGoogle Scholar
  25. de Mulder M, van der Ploeg T, de Waard GA, Boersma E, Umans VA: Admission glucose does not improve grace score at 6 months and 5 years after myocardial infarction. Cardiology. 2011, 120: 227-234. 10.1159/000335715.View ArticlePubMedGoogle Scholar
  26. Pinkau T, Mann JF, Ndrepepa G, Mehilli J, Hadamitzky M, Braun S, Kastrati A, Schomig A: Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis. 2004, 44: 627-635. 10.1053/j.ajkd.2004.05.045.View ArticlePubMedGoogle Scholar
  27. Morel O, El GS, Jesel L, Radulescu B, Meyer N, Wiesel ML, Caillard S, Campia U, Moulin B, Gachet C, Ohlmann P: Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired p2y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011, 57: 399-408. 10.1016/j.jacc.2010.09.032.View ArticlePubMedGoogle Scholar
  28. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003, 108: 2769-2775. 10.1161/01.CIR.0000103623.63687.21.View ArticlePubMedGoogle Scholar
  29. Bertomeu-Gonzalez V, Nunez J, Nunez E, Facila L, Sanchis J, Bodi V, Pellicer M, Bosch MJ, Martinez A, Chorro FJ, Llacer A: Prognostic effect of renal dysfunction after st-segment elevation myocardial infarction with and without heart failure. Int J Cardiol. 2006, 112: 159-165. 10.1016/j.ijcard.2005.08.031.View ArticlePubMedGoogle Scholar
  30. Heer T, Schiele R, Schneider S, Gitt AK, Wienbergen H, Gottwik M, Gieseler U, Voigtlander T, Hauptmann KE, Wagner S, Senges J: Gender differences in acute myocardial infarction in the era of reperfusion (the mitra registry). Am J Cardiol. 2002, 89: 511-517. 10.1016/S0002-9149(01)02289-5.View ArticlePubMedGoogle Scholar
  31. Hailer B, Naber C, Koslowski B, Van LP, Schafer H, Budde T, Jacksch R, Sabin G, Erbel R: Gender-related differences in patients with st-elevation myocardial infarction: results from the registry study of the st elevation myocardial infarction network essen. Clin Cardiol. 2011, 34: 294-301. 10.1002/clc.20916.View ArticlePubMedGoogle Scholar
  32. Damman P, Kikkert WJ, Woudstra P, Kuijt WJ, Grundeken MJ, Harskamp RE, Baan J, Vis MM, Henriques JP, Piek JJ, van Straalen JP, Fischer JC, Tijssen JG, de Winter RJ: Gender difference in the prognostic value of estimated glomerular filtration rate at admission in st-segment elevation myocardial infarction: a prospective cohort study. BMJ Open. 2012, 2 (2): e000322-doi:10.1136/bmjopen-2011-000322View ArticlePubMedPubMed CentralGoogle Scholar
  33. Jensen LO, Maeng M, Thayssen P, Tilsted HH, Terkelsen CJ, Kaltoft A, Lassen JF, Hansen KN, Ravkilde J, Christiansen EH, Madsen M, Sørensen HT, Thuesen L: Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012, 109: 629-635. 10.1016/j.amjcard.2011.10.018.View ArticlePubMedGoogle Scholar
  34. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/14/15/prepub

Copyright

© Sabroe et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.